title: Dorzolamide and timolol saves retinal ganglion cells in glaucomatous adult rats.
abstract: OBJECTIVE
  This study was designed to evaluate the effects of a dorzolamide-timolol combination or dorzolamide on retinal ganglion cell (RGC) density and intraocular pressure (IOP) in glaucomatous eyes of adult rats.
  
  
  METHODS
  Glaucoma was induced in the right eye of adult Wistar rats by episcleral venous occlusion. One experimental group was administered dorzolamide 2%-timolol 0.5% combination eye drops, while the other experimental group was administered dorzolamide 2% eye drops. Control groups had surgery without drug administration. Drug application was initiated either 2 weeks before surgery (Group A), from the day of surgery (Group B), 2 weeks after surgery (Group C), or 4 weeks after surgery (Group D). RGCs were labeled by intratectal Fluorogold injections and counted from flat-mount preparations, and IOP was measured using Tonopen.
  
  
  RESULTS
  Both dorzolamide-timolol combination and dorzolamide, when applied topically, significantly reduced IOP and improved RGC densities in experimental eyes when compared to control eyes. Earlier initiation, as well as longer duration of drug application, resulted in higher RGC densities.
  
  
  CONCLUSIONS
  Topical application of a dorzolamide-timolol combination or dorzolamide saved RGCs to a significant extent and reduced IOP in glaucomatous rat eyes.
authors.affiliation: Department of Ophthalmology & Cell Biology and Anatomy, New York Medical College, Valhalla, NY 10595, USA.
authors.forename: Vimal
authors.initials: V
authors.lastname: Sarup
authors.forename: Gavin C
authors.initials: GC
authors.lastname: McEwan
authors.forename: Carl
authors.initials: C
authors.lastname: Thompson
authors.forename: Kiran A
authors.initials: KA
authors.lastname: Patil
authors.forename: Sansar C
authors.initials: SC
authors.lastname: Sharma
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002452:Cell Count; D004195:Disease Models, Animal; D004338:Drug Combinations; D005260:Female; D005901:Glaucoma / Q000188:drug therapy* / Q000503:physiopathology; D007429:Intraocular Pressure / Q000187:drug effects*; D010865:Pilot Projects; D051381:Rats; D017208:Rats, Wistar; D012165:Retinal Ganglion Cells / Q000166:cytology / Q000187:drug effects*; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use*; D013876:Thiophenes / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D013999:Timolol / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D004338:Drug Combinations; D013449:Sulfonamides; D013876:Thiophenes; D013999:Timolol; C062765:dorzolamide